A Spanish PRISM real-world survey of 149 people with Parkinson's and 38 caregivers found high motor and non-motor symptom burden, widespread levodopa use, a 57% rate of reported impulse control behaviors, low use of rehabilitation therapies, and strong interest but low participation in clinical…

While not providing mechanistic or therapeutic leads, the dataset identifies clear unmet clinical needs, high non-motor and impulse-control symptom prevalence, and potential opportunities to improve care delivery and design/target recruitment for interventional trials in Spain.

INTRODUCTION: Real-world data studies are a promising option for understanding everyday Parkinson's disease (PD) management and optimizing strategies and therapeutic options. The Parkinson's Real-World Impact Assessment (PRISM) project was conceived as a European survey to evaluate the burden of the disease in people with Parkinson's disease (PwP) and their caregivers. Here, we present the analysis of the Spanish PRISM cohort dataset to describe prescribing patterns, healthcare resource utilization, and the impact of PD on PwP and their caregivers. METHODS: Data were collected using an electronic questionnaire distributed through different patient advocacy groups and specialized PD clinics in Spain. RESULTS: A total of 149 PwP (mean age, 62.6 years; mean disease duration, 7.6 years) and 38 caregivers were included. Most PwP (87.1%) received levodopa during the 12 months preceding the survey. A high percentage of patients (62.1%) expressed interest in participating in a clinical trial, but only 20% reported a current or previous enrollment. PwP reported high incidence of non-motor symptoms and poor health-related quality of life. At least one impulse control behavior was reported in 57% of patients. Caregivers reported mild to moderate disease burden. CONCLUSIONS: This study identified high rates of motor and non-motor symptoms, impulse control disorders, and considerable disease burden in PwP and their caregivers, even at a relatively young age and a mild/moderate stage of the disease. Also, it highlights the limited use of rehabilitation therapies. These data provide information for PD management and resource utilization in Spain.